Trial Profile

Path to Prevention (P2P) platform trial of risvodetinib for Parkinson's Research

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 12 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Risvodetinib (Primary)
Indications Parkinson's disease
Focus Therapeutic Use

Most Recent Events

12 Feb 2026 New trial record
27 Jan 2026 According to ABLi Therapeutics media release, company announced that it has entered into a collaboration agreement with The Michael J. Fox Foundation for Parkinsons Research (MJFF) to include ABLis lead candidate, risvodetinib, in the MJFF-sponsored Path to Prevention (P2P) platform trial. The multi-arm P2P trial, expected to launch in the coming months

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com